세계의 바이오시뮬레이션 시장은 예측 기간(2026-2036년)에서 CAGR 16.5%로 성장하며, 2026년 61억 5,000만 달러에서 2036년에는 약 285억 달러에 달할 것으로 전망되고 있습니다.
이 보고서는 세계 5대 지역의 바이오시뮬레이션 시장에 대한 상세한 분석을 제공하며, 현재 시장 동향, 시장 규모, 최근 동향 및 2036년까지의 예측에 중점을 두고 있습니다. 광범위한 2차 및 1차 조사와 시장 시나리오에 대한 심층 분석을 통해 주요 산업 촉진요인, 억제요인, 기회 및 과제에 대한 영향 분석을 수행합니다.
바이오시뮬레이션 시장의 성장을 이끄는 주요 요인으로는 정밀의료에 대한 전 세계적인 관심 증가, 비실리콘 의약품 개발의 급속한 확대, 엄격한 규제 요건, 시험 비용 절감의 필요성 등이 있습니다. 또한 인공지능(AI)과 머신러닝의 급속한 보급, 고성능 약동학 및 약력학 모델링에 대한 수요 증가, 첨단 계산 효율성, 디지털 전환(DX)의 추진은 바이오시뮬레이션 시장에서 사업을 운영하는 기업에게 큰 성장 기회를 창출할 것으로 예측됩니다.
Biosimulation Market by Product & Service (Software, Services), Application (Drug Development, Drug Discovery, Personalized Medicine, Others), and End User (Pharmaceutical & Biotechnology Companies, CROs, Academic & Research Institutes) - Global Forecast to 2036
According to the research report titled, 'Biosimulation Market by Product & Service (Software, Services), Application (Drug Development, Drug Discovery, Personalized Medicine, Others), and End User (Pharmaceutical & Biotechnology Companies, CROs, Academic & Research Institutes) - Global Forecast to 2036,' the global biosimulation market is expected to reach approximately USD 28.50 billion by 2036 from USD 6.15 billion in 2026, at a CAGR of 16.5% during the forecast period (2026-2036).
The report provides an in-depth analysis of the global biosimulation market across five major regions, emphasizing the current market trends, market sizes, recent developments, and forecasts till 2036. Following extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges.
The major factors driving the growth of the biosimulation market include the intensifying global focus on precision medicine, rapid expansion of in-silico drug development, stringent regulatory requirements, and the need to reduce trial costs. Additionally, the rapid expansion of artificial intelligence and machine learning, increasing need for high-performance pharmacokinetic and pharmacodynamic modeling, advanced computational efficiency, and digital transformation initiatives are expected to create significant growth opportunities for players operating in the biosimulation market.
The biosimulation market is segmented by product & service (software, services), application (drug development, drug discovery, personalized medicine, others), end user (pharmaceutical & biotechnology companies, CROs, academic & research institutes), and geography. The study also evaluates industry competitors and analyzes the market at the country level.
Based on Product & Service
By product & service, the software segment holds the largest market share in 2026, primarily attributed to its support for molecular modeling, complex diagnostics, and trial design in diverse research environments. These platforms offer comprehensive capabilities for predictive modeling and simulation. However, the services segment is expected to grow at a rapid CAGR during the forecast period, driven by the growing need for contract research, implementation support, and specialized consulting services. The ability to provide integrated solutions with expert support makes services highly attractive for modern pharmaceutical infrastructure.
Based on Application
By application, the drug development segment holds the largest share of the overall market in 2026, primarily due to its proven efficacy in handling high-volume clinical trial projects and providing scalable, performance-optimized solutions. The personalized medicine segment is expected to witness the fastest growth during the forecast period, driven by the shift toward precision medicine approaches, genomic analysis integration, and the complexity of advanced personalized treatment requirements. Both segments represent distinct operational requirements and technological specifications.
Based on End User
By end user, the pharmaceutical & biotechnology companies segment holds the largest share of the overall market in 2026, due to their superior data management capacity, high-performance systems, and extensive R&D investments. The CROs segment is expected to grow at a significant CAGR during the forecast period, driven by increased demand for outsourced research services, commercial logistics support, and specialized formulation expertise. Academic & research institutes represent an emerging segment with growing adoption of biosimulation tools for research and training purposes.
Geographic Analysis
An in-depth geographic analysis of the industry provides detailed qualitative and quantitative insights into the five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) and the coverage of major countries in each region. In 2026, North America dominates the global biosimulation market with the largest market share, primarily attributed to massive investments in biotech R&D and the presence of leading technology innovators in the United States and Canada. Asia-Pacific is expected to witness the fastest growth during the forecast period, supported by aggressive digital transformation initiatives and rapid adoption of advanced clinical services in China, India, and Japan. Europe, Latin America, and the Middle East & Africa represent emerging markets with growing pharmaceutical R&D investments and increasing demand for advanced biosimulation technologies.
Key Players
The key players operating in the global biosimulation market are Certara USA Inc., Simulations Plus Inc., Schrodinger Inc., Schrodinger, Genedata AG, Rhenovia Pharma, Entellus Consulting, Exscientia Ltd., Cyclica Inc., Atomwise Inc., and various other regional and emerging manufacturers, among others.
Key Questions Answered in the Report-
Biosimulation Market Assessment -- by Product & Service
Biosimulation Market Assessment -- by Application
Biosimulation Market Assessment -- by End User
Biosimulation Market Assessment -- by Geography